Biotech Stocks Under Scanner -- Rexahn Pharma, Peregrine Pharma, Immunomedics, and Protalix BioTherapeutics

Monday, May 8, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 8, 2017 /PRNewswire/ -- has issued research reports on these following stocks: Rexahn

Pharmaceuticals Inc. (NYSE MKT: RNN), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Immunomedics Inc. (NASDAQ: IMMU), and Protalix BioTherapeutics Inc. (NYSE MKT: PLX). According to an article on Barron's, US President Trump is scheduled to meet with
Biotech industry leaders on Monday, May 08th, 2017. As per Goldman Sachs' options strategists, drug prices will likely be a key topic, and investors should keep an eye on the sector for any changes to skew after the meeting. You can access our complimentary research reports on these stocks now at:

Rexahn Pharma  

Rockville, Maryland-based Rexahn Pharmaceuticals Inc.'s stock finished last Friday's session 882.14% higher at $3.85. A total volume of 636,822 shares was traded. Shares of the Company, which discovers, develops, and commercializes treatments for cancer, have a Relative Strength Index (RSI) of 95.64.

On May 04th, 2017, Rexahn Pharma announced financial results for Q1 ended March 31st, 2017. Cash and investments totaled approximately $18.5 million in Q1 2017; research and development expenses were $2.3 million; general and administrative expenses were approximately $1.7 million; and loss from operations was $4.0 million. Visit us today and download your complete report on RNN for free at:

Peregrine Pharma  

On Friday, shares in Tustin, California headquartered Peregrine Pharmaceuticals Inc. ended the session 2.58% higher at $0.61. The stock recorded a trading volume of 895,916 shares. The Company's shares have surged 97.42% in the previous three months. The stock is trading 45.17% above its 200-day moving average. Moreover, shares of Peregrine Pharma, which researches and develops monoclonal antibodies for the treatment of cancer in the US, have an RSI of 49.77.

On May 01st, 2017, Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharma, and MilliporeSigma announced that the former will upgrade its Myford clinical and commercial manufacturing facility with multiple Mobius® 2000-liter single-use bioreactors from MilliporeSigma. The new bioreactors, to be installed in mid-2017, provide Avid with the latest technology while expanding the Company's manufacturing capacity. The complimentary research report on PPHM can be accessed at:


Morris Plains, New Jersey headquartered Immunomedics Inc.'s shares surged 17.56%, closing the session at $6.36. A total volume of 24.55 million shares was traded, which was above their three months average volume of 3.85 million shares. The stock has gained 8.16% in the last one month, 44.55% over the previous three months, and 73.30% on an YTD basis. Shares of the Company are trading 8.61% and 62.29% above their 50-day and 200-day moving averages, respectively. Additionally, shares of Immunomedics, which focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases, have an RSI of 61.40.

On May 05th, 2017, research firm Wells Fargo upgraded the Company's stock rating from 'Market Perform' to 'Outperform'. Register for free on and download the PDF research report on IMMU at:

Protalix BioTherapeutics  

Last Friday at the close, shares in Carmiel, Israel-based Protalix BioTherapeutics Inc. recorded a trading volume of 901,749 shares. The stock ended the session 2.13% lower at $0.92. The Company's shares have advanced 17.95% over the previous three months and 104.44% since the start of this year. The stock is trading above its 200-day moving average by 30.47%. Furthermore, shares of Protalix BioTherapeutics, which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, have an RSI of 39.67.

On April 17th, 2017, research firm Rodman & Renshaw reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $4 a share to $5 a share.

On May 01st, 2017, Protalix BioTherapeutics announced that it will report Q1 2017 financial results and provide a corporate update on Wednesday, May 10th, 2017, at 8:30 a.m. ET. The conference call will be broadcast live and available for replay for two weeks under the Events Calendar of the Investors section of the Company's website. Get free access to your research report on PLX at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store